Navigation Links
Marshall Edwards Announces $2 Million Private Placement
Date:9/28/2011

SAN DIEGO, Sept. 28, 2011 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it has entered into a definitive agreement with its majority shareholder, Novogen Limited, to sell common stock in a private placement for gross proceeds of $2 million, before deducting fees and expenses of the offering, through the sale of approximately 1.33 million shares of common stock. The offering is expected to close on September 30, 2011, subject to certain customary closing conditions.

"This transaction is another indication of Novogen's ongoing support of Marshall Edwards and our emerging oncology programs," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of Marshall Edwards. "Net proceeds from this offering will be used to continue development of our two lead drug candidates, ME-143 and ME-344, and will enable us to advance these programs to meaningful clinical data points next year that we believe can create significant value for our shareholders."

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Marshall Edwards, Inc. nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
2. Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
3. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
4. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
5. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
6. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
7. Marshall Edwards Announces Private Placement
8. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
9. Marshall Edwards Receives Positive Response From NASDAQ
10. Marshall Edwards to Host Annual Meeting of Stockholders
11. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015 For the past 15 ... accidents per year in the U.S. alone (U.S. Census Bureau 2012). ... are minor fender benders BUT there are quite a few where ... cabin intrusion, which can obstruct the seatbelt release button or occupant ... being in any serious accidents in their lifetime but may still ...
(Date:3/2/2015)... Following announcements from both Novartis and ... Inc. (NASDAQ:  ARRY) today announced the completion of ... Novartis.  Along with global ownership of both assets, ... million from Novartis. Ron Squarer, Chief ... the Novartis-GSK transaction, Array now owns both binimetinib ...
(Date:3/2/2015)... , March 2, 2015 Leading patient ... kicking off the 2015 One Million Strong ... national campaign will raise awareness and funds for colorectal ... than one million colorectal cancer survivors living in ... disease with great strength and courage every day. ...
Breaking Medicine Technology:New SuperVizor, an Automobile Escape Tool, Ensures the Safety of Drivers and Passengers on the Road 2Array Announces Completion Of Binimetinib And Encorafenib Transactions 2Array Announces Completion Of Binimetinib And Encorafenib Transactions 3Array Announces Completion Of Binimetinib And Encorafenib Transactions 4Array Announces Completion Of Binimetinib And Encorafenib Transactions 5Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 2Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 3Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 4Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 5
... Tolerx, Inc. and GlaxoSmithKline (GSK) today ... an investigational humanized anti-CD3 monoclonal antibody, did not meet ... month 12 in patients with new-onset autoimmune type 1 ... data, no new or unexpected treatment-related safety concerns have ...
... MATEO, Calif., March 11, 2011 Sonitus Medical, Inc., ... non-surgical and removable hearing prosthetic to transmit sound via ... Mark certification for its SoundBite Hearing System. The company ... Assurance System Approval. This is the first European regulatory ...
Cached Medicine Technology:Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint 2Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint 3Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint 4Sonitus Medical Receives European CE Mark for SoundBite™ Hearing System 2
(Date:3/2/2015)... (PRWEB) March 02, 2015 Ticket Down ... at the Hollywood Bowl . This popular site has ... appreciation promo code JIMMY-BUFFETT-2015 for added savings. , Parrotheads ... favorite performer will be headlining at the Hollywood Bowl ... will be on Thursday, October 22nd and it will ...
(Date:3/2/2015)... 02, 2015 Doctors in Novara, Italy ... better predictor of outcomes for people with mesothelioma than ... of the new study on the Surviving Mesothelioma ... University of Eastern Piedmont followed the cases of 172 ... for excess lung fluid. , “Persistent lung expansion ...
(Date:3/2/2015)... March 02, 2015 Burns Engineering's ... calibration for Secondary Standard Platinum Resistance Thermometers (SSPRTs) ... business days or less . . . guaranteed. ... ® Accredited (Lab Code 200706-0), ISO 9001 and ... Temperature range is -196°C to 500°C, both ITS-90 ...
(Date:3/2/2015)... 02, 2015 The minimally invasive ... a CAGR of 6.1% to reach $14,133.0 million ... , Factors such as advantages of minimally invasive ... owing to minimally invasive surgeries and increasing number ... driving the global minimally invasive surgical instruments market. ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Four Seasons Resort ... celebrating its 25th anniversary this year, having officially opened its ... the luxury resort is honoring over 70 employees who started ... -- from amongst the approximately 400 original employees. The ... Resort’s Oceanfront Lawn. , This Four Seasons flagship ...
Breaking Medicine News(10 mins):Health News:Cheap Jimmy Buffett Tickets Hollywood Bowl: Ticket Down Slashes Prices on Jimmy Buffett Tickets at the Hollywood Bowl in Los Angeles/Hollywood, CA 2Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2
... ANN ARBOR, Mich. A mutant protein found in nearly ... cancer,s development but in its continued growth, according to a ... The finding suggests a possible target for developing new ways ... mutations in the Kras gene are what cause pancreatic cancer ...
... largest studies to investigate lumbar spine disc degeneration found ... more likely to have disc degeneration than those with ... resonance imaging (MRI) show elevated BMI is associated with ... greater severity of disc degeneration, including narrowing of the ...
... Jan. 28 (HealthDay News) -- For some people a change in ... depression, according to an expert who describes how to cope with ... ambient light, said Dr. Dan Iosifescu, director of the Mount Sinai ... "A gland in our brain provides a time signal, based on ...
... , FRIDAY, Jan. 27 (HealthDay News) -- Eating a high-fiber ... a low-fiber diet might, according to a new study that ... a disease of the intestines in which pouches develop in ... Carolina School of Medicine analyzed data from more than 2,100 ...
... 2012 Researchers at UT Southwestern Medical Center have developed ... a new imaging technique to diagnose brain tumors. The unique ... tumors are located in areas of the brain too dangerous ... provides a definitive diagnosis of cancer based on imaging of ...
... News) -- Positive reinforcement, such as receiving small, unexpected ... to help patients with high blood pressure take their ... black Americans. The findings are significant because poor ... death, the researchers from the Center for Healthful Behavior ...
Cached Medicine News:Health News:Gene linked to pancreatic cancer growth, U-M study finds 2Health News:Lumbar disc degeneration more likely in overweight and obese adults 2Health News:Lumbar disc degeneration more likely in overweight and obese adults 3Health News:Winter Doldrums Got You Down? Here's How to Bounce Back 2Health News:Common Gastro Disease Occurs Even With High-Fiber Diet 2Health News:Diagnostic brain tumor test could revolutionize care of patients 2Health News:Positive Reinforcement May Help Patients Take Their Meds 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: